40 results on '"Heinen Y"'
Search Results
2. Microvascular tissue perfusion after postcatheterization pseudoaneurysm treatment
- Author
-
Stern, M., primary, Schremmer, J., additional, Scharm, S., additional, Baasen, S., additional, Heinen, Y., additional, Sansone, R., additional, Polzin, A., additional, Jung, C., additional, Heiss, C., additional, Kelm, M., additional, and Busch, L., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Angioplasty of flow limiting stenosis improves left ventricular diastolic dysfunction in patients with peripheral artery disease
- Author
-
Baasen, S, primary, Stern, M, additional, Heinen, Y, additional, Goerdes, L, additional, Sansone, R, additional, Heiss, C, additional, Kelm, M, additional, and Busch, L, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of peripheral angioplasty on wound oxygenation measured with near-infrared spectroscopy in patients with critical limb ischemia
- Author
-
Foerster, R, primary, Stern, M, additional, Heinen, Y, additional, Baasen, S, additional, Sansone, R, additional, Heiss, C, additional, Kelm, M, additional, and Busch, H L, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Uninterrupted direct oral anticoagulants and vitamin K antagonists during ablation for atrial fibrillation: an updated meta-analysis
- Author
-
Brockmeyer, M, primary, Lin, Y, additional, Parco, C, additional, Karathanos, A, additional, Krieger, T, additional, Schulze, V, additional, Heinen, Y, additional, Bejinariu, A, additional, Mueller, P, additional, Makimoto, H, additional, Kelm, M, additional, and Wolff, G, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Standardized risk management in catheterization procedures for non-ST-segment elevation myocardial infarction: associations with in-hospital clinical outcomes
- Author
-
Troestler, J, primary, Parco, C, additional, Brockmeyer, M, additional, Lin, Y, additional, Krieger, T, additional, Quade, J, additional, Bader, S, additional, Kosejian, L, additional, Karathanos, A, additional, Heinen, Y, additional, Schulze, V, additional, Icks, A, additional, Kelm, M, additional, and Wolff, G, additional
- Published
- 2020
- Full Text
- View/download PDF
7. P6268Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials
- Author
-
Lin, Y, primary, Parco, C, additional, Brockmeyer, M, additional, Karathanos, A, additional, Schulze, V, additional, Krieger, T, additional, Heinen, Y, additional, Perings, S, additional, Kelm, M, additional, and Wolff, G, additional
- Published
- 2019
- Full Text
- View/download PDF
8. 283Endovascular thrombectomy as a means to improve survival in acute ischemic stroke - A meta-analysis
- Author
-
Lin, Y, primary, Schulze, V, additional, Brockmeyer, M, additional, Parco, C, additional, Karathanos, A, additional, Krieger, T, additional, Heinen, Y, additional, Gliem, M, additional, Hartung, H P, additional, Antoch, G, additional, Jander, S, additional, Turowski, B, additional, Perings, S, additional, Kelm, M, additional, and Wolff, G, additional
- Published
- 2019
- Full Text
- View/download PDF
9. P957Survival benefits of routine glycoprotein IIb/IIIa inhibitors during primary PCI in ST-segment elevation myocardial infarction: A meta-analysis of randomised controlled trials
- Author
-
Karathanos, A, primary, Lin, Y F, additional, Dannenberg, L, additional, Parco, C, additional, Schulze, V, additional, Brockmeyer, M, additional, Krieger, T, additional, Jung, C, additional, Heinen, Y, additional, Perings, S, additional, Zeymer, U, additional, Kelm, M, additional, Polzin, A, additional, and Wolff, G, additional
- Published
- 2019
- Full Text
- View/download PDF
10. P2792Preoperative levosimendan improves survival in patients with low cardiac output syndrome undergoing cardiac surgery: a meta-analysis of randomized controlled trials
- Author
-
Brockmeyer, M, primary, Lin, Y, additional, Karathanos, A, additional, Parco, C, additional, Krieger, T, additional, Heinen, Y, additional, Albert, A, additional, Kelm, M, additional, Schulze, V, additional, and Wolff, G, additional
- Published
- 2019
- Full Text
- View/download PDF
11. P3624Glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
- Author
-
Wolff, G, primary, Karathanos, A, additional, Dannenberg, L, additional, Lin, Y, additional, Brockmeyer, M, additional, Heinen, Y, additional, Zeus, T, additional, Kelm, M, additional, Polzin, A, additional, and Schulze, V, additional
- Published
- 2018
- Full Text
- View/download PDF
12. P3593Interventional patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials
- Author
-
Wolff, G, primary, Lin, Y, additional, Karathanos, A, additional, Brockmeyer, M, additional, Heinen, Y, additional, Zeus, T, additional, Polzin, A, additional, Kelm, M, additional, and Schulze, V, additional
- Published
- 2018
- Full Text
- View/download PDF
13. P6355Validation of an NCDR-score-based risk model for cardiac catheterization procedures in a european population
- Author
-
Wolff, G, primary, Lin, Y, additional, Quade, J, additional, Bader, S, additional, Kosejian, L, additional, Karathanos, A, additional, Brockmeyer, M, additional, Heinen, Y, additional, Kelm, M, additional, and Schulze, V, additional
- Published
- 2018
- Full Text
- View/download PDF
14. Risk and time preferences in individuals with lifestyle-related and non-lifestyle-related cardiovascular diseases: a pilot study.
- Author
-
Kairies-Schwarz N, Mussio I, Bulla-Holthaus N, Wankmüller E, Wolff G, Gontscharuk V, Heinen Y, Perings S, Brockmeyer M, Kelm M, and Icks A
- Subjects
- Humans, Pilot Projects, Male, Female, Cross-Sectional Studies, Middle Aged, Aged, Patient Preference, Adult, Surveys and Questionnaires, Health Behavior, Germany epidemiology, Risk-Taking, Cardiovascular Diseases, Life Style
- Abstract
Objectives: To (1) pilot a study of behavioural characterisation based on risk and time preferences in clinically well-characterised individuals, (2) assess the distribution of preferences in this population and (3) explore differences in preferences between individuals with 'lifestyle-related' (LS) and 'non-lifestyle-related' (NLS) cardiovascular diseases., Design: Cross-sectional study with an economic online experiment to collect risk and time preferences, a detailed clinical characterisation and a sociodemographic and lifestyle survey. A definition of LS and NLS groups was developed., Setting: Specialist outpatient clinics of the clinic for cardiology and pneumology of the University Hospital Düsseldorf and patients from a cardiology practice in Düsseldorf., Participants: A total of 74 individuals with cardiovascular diseases., Outcomes: Risk and time preferences., Results: The implementation of the study process, including participant recruitment and data collection, ran smoothly. The medical checklist, the survey and the time preference instrument were well received. However, the conceptual understanding of the risk preference instrument resulted in inconsistent choices for many participants (47%). The remaining individuals were more risk averse (27%) than risk seeking (16%) and risk neutral (10%). Individuals in our sample were also more impatient (49%) than patient (42%). The participant classification showed that 65% belonged to the LS group, 19% to the NLS group and 16% could not be assigned (unclear allocation to lifestyle (ULS) group). Excluding the ULS group, we show that individuals in the LS group were more risk seeking, and unexpectedly, more patient than those in the NLS group., Conclusions: The process of the pilot study and its results can be used as a basis for the design of the main study. The differences in risk and time preferences between the LS and NLS groups provide us with a novel hypothesis for unhealthy behaviours: individuals never give up a bad habit, they simply postpone the latter, which can be tested alongside other additional research questions., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
15. Risk-adjusted management in catheterization procedures for non-ST-segment elevation myocardial infarction: A standard operating procedure pilot study.
- Author
-
Parco C, Tröstler J, Brockmeyer M, Hoss A, Lin Y, Quade J, Heinen Y, Schulze V, Jung C, Icks A, Kelm M, and Wolff G
- Subjects
- Humans, Male, Aged, Female, Pilot Projects, Risk Factors, Hemorrhage, Catheterization adverse effects, Registries, Treatment Outcome, Hospital Mortality, Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction epidemiology, ST Elevation Myocardial Infarction surgery
- Abstract
Background: The effects of standardized risk-adjusted periprocedural management of cardiac catheterization procedures in Non-ST segment elevation myocardial infarction (NSTEMI) remain unknown. We implemented a standard operating procedure (SOP) specifying risk assessment (RA, using National Cardiovascular Data Registry (NCDR) risk models) and risk-adjusted management (RM, e.g. intensified monitoring) in 2018 and aimed to investigate staff SOP adherence and associations with patient outcomes., Methods and Results: All 430 invasively managed NSTEMI patients (mean age 72y; 70.9% male) in 2018 were analyzed for staff SOP adherence and in-hospital clinical outcomes. 207 patients (48.1%; RM+) received both RA and RM; 92 patients (21.4%; RM-) received RA but no RM; 131 patients (30.5%; RA-) received neither RA nor RM. Lower staff adherence to RA was associated with emergency settings (51.9% (RA-) vs. 22.1% (RA+); p<0.01), presentation in cardiogenic shock (17.6% (RA-) vs. 6.4% (RA+); p<0.01) and invasive mechanical ventilation (12.2% (RA-) vs. 3.3% (RA+); p<0.01). Early sheath removal (87.9% (RM+) vs. 56.5% (RM-); p<0.01) and intensified monitoring (p<0.01) were more frequent in the RM+ group. All-cause mortality was not different (1.4% (RM+) vs. 4.3% (RM-); p=0.13), but there were fewer major bleeding events with associated with RM (2.4% (RM+) vs. 12% (RM-); p<0.01), which remained independently associated with RM in a multivariate logistic regression model correcting for confounders (p<0.01)., Conclusion: In an all-comer patient cohort with NSTEMI, staff adherence to risk-adjusted periprocedural management was independently associated with fewer major bleeding events. Staff adherence to SOP-specified risk assessment was frequently neglected in more critical clinical situations., Competing Interests: Declaration of Competing Interest All authors declare: no support from any industry or third-party organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Comparison of costs associated with transcatheter mitral valve repair: PASCAL vs MitraClip in a real-world setting.
- Author
-
Haurand JM, Haschemi J, Oehler D, Heinen Y, Polzin A, Kelm M, and Horn P
- Subjects
- Humans, Prospective Studies, Retrospective Studies, Hospital Costs, Mitral Valve surgery, Cardiac Surgical Procedures
- Abstract
Aims: We aimed to conduct a clinical process cost analysis to evaluate all upcoming costs of mitral valve transcatheter edge-to-edge repair (M-TEER) treatment using the MitraClip and the PASCAL repair system., Methods: First, we prospectively enrolled 107 M-TEER patients treated with either the PASCAL or MitraClip system and compared all upcoming costs during the M-TEER procedure and the associated in-hospital stay. Second, we retrospectively analysed 716 M-TEER procedures with regard to the occurrence of complications and their associated costs. All materials used in the catheterization laboratory for the procedures were evaluated. The cost analysis considered various expenses, such as general in-hospital costs, device costs, catheter laboratory and material costs., Results: In the prospective study, 51 patients were treated using the PASCAL system, and 56 were treated using the MitraClip system. The two groups had comparable baseline characteristics and comorbidities. The total in-hospital costs were 25 414 (Interquartile range (IQR) 24 631, 27 697) € in the PASCAL group and 25 633 (IQR 24 752, 28 256) € in the MitraClip group (p = 0.515). The major cost driver was initial material expenditure, mostly triggered by device costs, which were similar to the PASCAL and MitraClip systems. Overall intensive care unit and general ward costs did not differ between the PASCAL and MitraClip groups. In the retrospective analysis, M-TEER-related complications were rare but were associated with higher costs, mainly due to prolonged hospitalisation., Conclusion: The major cost driver of M-TEER was the material expenditure, which was mostly triggered by high device costs. The costs of treating patients were similar for the PASCAL and MitraClip systems. M-TEER-related complications are associated with higher costs, mainly due to prolonged hospitalisation. This analysis provides valuable insights into reducing expenses by modifying the process of M-TEER., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
17. Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease.
- Author
-
Brockmeyer M, Wies E, Joerges J, Sommer J, Borgmann SO, Chernyak N, Lin Y, Parco C, Schulze V, Heinen Y, Kelm M, Icks A, Perings S, and Wolff G
- Subjects
- Humans, Male, Female, Cholesterol, LDL, Goals, Glycated Hemoglobin, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Atherosclerosis, Diabetes Mellitus, Dyslipidemias diagnosis, Dyslipidemias drug therapy, Dyslipidemias epidemiology
- Abstract
Background/hypothesis: Risk factor control of diabetes mellitus (DM) and especially dyslipidemia remains unsatisfactory in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to analyze the knowledge of low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (HbA1c) treatment goals, subjective level of information, and information needs in very high-risk patients with ASCVD., Methods: ASCVD patients (n = 210; 75 ± 9 years; 71.4% male; 89.5% coronary disease) with DM (96.7% type 2) completed a questionnaire assessing knowledge of HbA1c and LDL-C treatment goals and subjective level of information and information needs on disease-related topics of DM and ASCVD. Serum LDL-C and HbA1c were measured., Results: HbA1c goal (<7.0% in 60.6%) was attained more frequently than LDL-C goal (<70 mg/dl in 39.9%; p < .01). Significantly more participants named the correct goal for HbA1c compared to LDL-C (52.9% vs. 2.4%; p < .01). Subjective levels of information were higher and information needs were lower for DM than for ASCVD (p < .01 for all topics). No associations of knowledge of treatment goals and level of information with the attainment of treatment goals for HbA1c and LDL-C were found. However, in multivariate regression, higher levels of education were associated with knowledge of treatment goals (HbA1c: odds ratio [OR] 1.32, 95% confidence interval [CI] 1.01-1.72, p = .04; LDL-C: OR 2.32, 95% CI 1.07-5.03; p = .03)., Conclusion: In very high-risk patients with ASCVD, a deficit of knowledge of treatment goals to control dyslipidemia exists when compared to DM, patients felt significantly better informed for topics of DM than for ASCVD and display higher information needs for topics of ASCVD., (© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
18. Process Standardization in High-Risk Coronary Interventions is Associated With Quality of Care Measures.
- Author
-
Heinen Y, Wolff G, Klein K, Brockmeyer M, Parco C, Perings S, Zeus T, Kelm M, Icks A, and Jung C
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Middle Aged, Reference Standards, Retrospective Studies, Treatment Outcome, Coronary Artery Disease diagnosis, Coronary Artery Disease surgery, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Patient safety is one of the most important issues in healthcare. High-risk percutaneous coronary interventions (HR-PCIs) offer well-established treatment options for patients with complex coronary artery disease and multiple comorbidities. Whether process standardization using standard operating procedure (SOP) management and checklists improves HR-PCI is still unknown., Methods and Results: This retrospective study analyzed procedural characteristics, in-hospital outcomes, and length of hospital stay in patients who received HR-PCI in a German heart center 12 months before the introduction of process standardization using SOP management-the SOP (-) group-and after the introduction of process standardization using SOP management-the SOP (+) group. A total of 192 patients were included, with 77 patients in the SOP (-) group and 115 patients in the SOP (+) group. The mean age in the SOP (-) group was 72.0 ± 10.2 years and 81.8% were male; mean age in the SOP (+) group was 75.2 ± 10.4 years and 68.7% were male. Acute kidney events were significantly lower in the SOP (+) group than in the SOP (-) group (7.0% vs 10.4%; P=.04). Bleeding was the most common adverse event and significantly lower in the SOP (+) group than in the SOP (-) group (13.1% vs 31.2%, respectively; P<.01). There were trends toward shorter length of hospital stay in the SOP (+) group compared with the SOP (-) group (9.3 ± 6.4 days vs 10.9 ± 7.3 days, respectively; P=.10) and days of hospital stay in the intensive care unit (3.7 ± 4.0 days vs 4.7 ± 4.3 days; P=.07). SOP management was independently associated with shorter length of hospital stay in multivariate regression analysis., Conclusion: This retrospective study shows significantly better quality of care measures after the introduction of process standardization techniques using SOP management in HRPCIs, with a lower risk of adverse outcomes and shorter length of hospital stay.
- Published
- 2022
- Full Text
- View/download PDF
19. Impact of high on-treatment platelet reactivity after angioplasty in patients with critical limb ischemia.
- Author
-
Busch L, Stern M, M'Pembele R, Dannenberg L, Mourikis P, Gröne M, Özaslan G, Heinen Y, Heiss C, Sansone R, Huhn R, Kelm M, and Polzin A
- Subjects
- Aged, Aged, 80 and over, Angioplasty, Clopidogrel adverse effects, Female, Humans, Male, Prospective Studies, Treatment Outcome, Chronic Limb-Threatening Ischemia, Platelet Aggregation Inhibitors adverse effects
- Abstract
Objectives: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard of care in patients with peripheral artery disease (PAD) after percutaneous transluminal angioplasty (PTA). However, high on treatment platelet reactivity (HTPR) to DAPT is frequent and associated with major adverse limb events (MALE) in PAD patients. Nevertheless, association of MALE and HTPR in patients with critical limb ischemia (CLI) is not known. Moreover, comorbidities might confound response to antiplatelet medication further. Hence, in this trial we analyzed pharmacodynamic responses to DAPT and clinical events in CLI patients post PTA., Methods: In this prospective single center pilot analysis, we included 71 CLI patients. Patients received DAPT after PTA. Antiplatelet effect were measured by light transmission aggregometry (LTA) and vasodilator-stimulated protein phosphorylation assay (VASP). MALE, major adverse cardiac and cerebrovascular events (MACCE) and BARC bleeding within 12 months follow-up were assessed., Results: Mean age of patients was 73.37 ± 7.36 years and 47 (66.2%) were male. Overall HTPR appeared in 46 patients (64.8%). MALE and MACCE showed no differences between patients with and patients without HTPR. However, bleeding was higher in patients with sufficient pharmacodynamic response to DAPT (Bleeding - HTPR: 13.4% vs. no HTPR: 36.0%; log-rank HR: 0.32; 95% CI 0.1079 to 0.9396 p = 0.0217). This finding remained robust in multivariate analysis., Conclusion: HTPR to DAPT is frequent in CLI patients. However, bleeding was higher in patients with sufficient response to DAPT. Ischemic events did not differ. Hence, CLI patients might benefit from an alternative antithrombotic approach., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Correction to: National Cardiovascular Data Registry-Acute Kidney Injury (NCDR) vs. Mehran risk models for prediction of contrast-induced nephropathy and need for dialysis after coronary angiography in a German patient cohort.
- Author
-
Parco C, Brockmeyer M, Kosejian L, Quade J, Tröstler J, Bader S, Lin Y, Sokolowski A, Hoss A, Heinen Y, Schulze V, Icks A, Jung C, Kelm M, and Wolff G
- Published
- 2021
- Full Text
- View/download PDF
21. National Cardiovascular Data Registry-Acute Kidney Injury (NCDR) vs. Mehran risk models for prediction of contrast-induced nephropathy and need for dialysis after coronary angiography in a German patient cohort.
- Author
-
Parco C, Brockmeyer M, Kosejian L, Quade J, Tröstler J, Bader S, Lin Y, Sokolowski A, Hoss A, Heinen Y, Schulze V, Icks A, Jung C, Kelm M, and Wolff G
- Subjects
- Contrast Media adverse effects, Coronary Angiography adverse effects, Humans, Registries, Renal Dialysis, Risk Assessment, Risk Factors, Acute Kidney Injury chemically induced, Acute Kidney Injury epidemiology, Acute Kidney Injury therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Contrast-induced nephropathy (CIN) is a major adverse event in patients undergoing coronary angiography. The Mehran risk model is the gold-standard for CIN risk prediction. However, its performance in comparison to more contemporary National Cardiovascular Data Registry-Acute Kidney Injury (NCDR-AKI) risk models remains unknown. We aimed to compare both in this study., Methods and Results: Predictions of Mehran and NCDR-AKI risk models and clinical events of CIN and need for dialysis were assessed in a total of 2067 patients undergoing coronary angiography with or without percutaneous coronary intervention. Risk models were compared regarding discrimination (receiver operating characteristic analysis), net reclassification improvement (NRI) and calibration (graphical and statistical analysis). The NCDR risk model showed superior risk discrimination for predicting CIN (NCDR c-index 0.75, 95% CI 0.72-0.78; vs. Mehran c-index 0.69, 95% CI 0.66-0.72, p < 0.01), and continuous NRI (0.22; 95% CI 0.12-0.32; p < 0.01) compared to the Mehran model. The NCDR risk model tended to underestimate the risk of CIN, while the Mehran model was more evenly calibrated. For the prediction of need for dialysis, NCDR-AKI-D also discriminated risk better (c-index 0.85, 95% CI 0.79-0.91; vs. Mehran c-index 0.75, 95% CI 0.66-0.84; p
NCDRvsMehran < 0.01), but continuous NRI showed no benefit and calibration analysis revealed an underestimation of dialysis risk., Conclusion: In German patients undergoing coronary angiography, the modern NCDR risk model for predicting contrast-induced nephropathy showed superior discrimination compared to the Mehran model while showing less accurate calibration. Results for the outcome 'need for dialysis' were equivocal., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
22. Angioplasty of Flow-Limiting Stenosis Reduces Aortic and Brachial Blood Pressure in Patients With Peripheral Artery Disease.
- Author
-
Busch L, Heinen Y, Stern M, Wolff G, Özaslan G, Tzetou K, Sansone R, Heiss C, and Kelm M
- Subjects
- Aged, Aged, 80 and over, Angioplasty methods, Aorta physiopathology, Brachial Artery physiopathology, Constriction, Pathologic diagnosis, Constriction, Pathologic physiopathology, Female, Humans, Hypertension diagnosis, Male, Middle Aged, Multivariate Analysis, Peripheral Arterial Disease diagnosis, Prospective Studies, Pulse Wave Analysis, Blood Pressure physiology, Hypertension physiopathology, Peripheral Arterial Disease physiopathology, Vascular Stiffness physiology
- Abstract
Background Arterial hypertension affects cardiovascular outcome in patients with peripheral artery disease (PAD). We hypothesized that angioplasty of peripheral arterial stenoses decreases aortic (aBP) and brachial blood pressure (bBP). Methods and Results In an index cohort (n=30), we simultaneously measured aBP, bBP, augmentation index (AIx), and aortic pulse wave velocity (PWV) before and after angioplasty of the iliac and femoropopliteal arteries; diagnostic angiography served as a control. In an all-comer registry cohort (n=381), we prospectively measured bBP in patients scheduled for angioplasty of the iliac, femoral, and crural arteries or diagnostic angiography. Systolic aBP decreased after iliac (Δ-25 mmHg; 95% CI, -30 to -20; P <0.0001) and femoropopliteal angioplasty (Δ-12 mmHg; 95% CI, -17 to -5; P <0.0001) as compared with diagnostic angiography. Diastolic aBP decreased after iliac (Δ-9 mmHg; 95% CI, -13 to -1; P =0.01) but not femoropopliteal angioplasty. In parallel, AIx significantly dropped, whereas PWV remained stable. In the registry cohort, systolic bBP decreased after angioplasty of the iliac (Δ-17 mmHg; 95% CI, -31 to -8; P =0.0005) and femoropopliteal arteries (Δ-10 mmHg; 95% CI, -23 to -1; P =0.04) but not the crural arteries, as compared with diagnostic angiography. Diastolic bBP decreased after iliac (Δ-10 mmHg; 95% CI, -17 to -2; P =0.01) and femoropopliteal angioplasty (Δ-9 mmHg; 95% CI, -15 to -1; P =0.04). Multivariate analysis identified baseline systolic bBP and site of lesion as determinants of systolic bBP drop after endovascular treatment. Conclusions Angioplasty of flow-limiting stenoses in patients with peripheral artery disease lowers aortic and brachial blood pressure with more pronounced effects at more proximal lesion sites and elevated baseline systolic blood pressure. These data indicate a role of endovascular treatment to acutely optimize blood pressure in patients with peripheral artery disease. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02728479.
- Published
- 2021
- Full Text
- View/download PDF
23. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
- Author
-
Brockmeyer M, Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Heinen Y, Bejinariu A, Müller P, Makimoto H, Kelm M, and Wolff G
- Subjects
- Administration, Oral, Anticoagulants adverse effects, Hemorrhage chemically induced, Hemorrhage epidemiology, Humans, Risk Factors, Vitamin K, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Catheter Ablation, Stroke epidemiology, Stroke etiology, Stroke prevention & control
- Abstract
Background: Periprocedural uninterrupted anticoagulation for catheter ablation of atrial fibrillation (AF) became standard after positive results of vitamin K antagonist (VKA) trials. Previous studies of uninterrupted direct oral anticoagulants (DOACs) vs. VKA have given controversial results. We thus aimed to elucidate the risk/benefit ratio of uninterrupted DOAC vs. VKA during catheter ablation of AF in an updated meta-analysis of randomised controlled trials (RCTs)., Methods: Online databases were searched for RCTs comparing uninterrupted DOAC to VKA in patients undergoing catheter ablation of AF. Data from retrieved studies were analysed in a comprehensive meta-analysis. Primary safety outcome was major bleeding; primary efficacy outcome was stroke or transient ischaemic attack (TIA). Secondary outcomes included a composite of major bleeding and stroke or TIA, minor bleeding, acute cerebral lesions on magnetic resonance imaging (MRI), and mortality., Results: Six eligible RCTs comprising 2,369 patients were included. There were no significant differences in DOAC vs. VKA concerning the rates of major bleeding (2.2% vs. 3.8%; odds ratio (OR) 0.69, 95% confidence interval (CI) 0.30-1.56; p = .37) and stroke or TIA (0.2% vs. 0.2%; OR 0.97, CI 0.20-4.72; p = .97). Pooled meta-analysis of secondary outcomes revealed no significant differences (OR 0.73, p = .49 for composite of major bleeding and stroke or TIA; OR 1.08, p = .52 for minor bleeding; OR 1.12, p = .59 for acute cerebral lesions on MRI; and OR 0.60, p = .64 for all-cause mortality)., Conclusion: Our meta-analysis suggests that uninterrupted DOAC is not superior to VKA in patients undergoing catheter ablation of AF with comparable rates of major bleeding and stroke.
- Published
- 2021
- Full Text
- View/download PDF
24. Modern NCDR and ACTION risk models outperform the GRACE model for prediction of in-hospital mortality in acute coronary syndrome in a German cohort.
- Author
-
Parco C, Brockmeyer M, Kosejian L, Quade J, Tröstler J, Bader S, Lin Y, Karathanos A, Krieger T, Heinen Y, Schulze V, Icks A, Jung C, Kelm M, and Wolff G
- Subjects
- Germany epidemiology, Hospital Mortality, Humans, Registries, Risk Assessment, Risk Factors, Acute Coronary Syndrome diagnosis
- Abstract
Background and Purpose: Risk prediction with the Global Registry of Acute Coronary Events (GRACE) risk model is guideline-recommended in acute coronary syndrome (ACS) patients. However, the performance of more contemporary scores derived from ACTION (Acute Coronary Treatment and Intervention Outcomes Network) and National Cardiovascular Data (NCDR) registries remains incompletely understood. We aimed to compare these models in German ACS patients., Methods and Results: A total of 1567 patients with (Non-)ST-segment elevation myocardial infarction (NSTEMI: 1002 patients, STEMI: 565 patients) undergoing invasive management at University Hospital Düsseldorf (Germany) from 2014 to 2018 were included. Overall in-hospital mortality was 7.5% (NSTEMI 3.7%, STEMI 14.5%). Parameters for calculation of GRACE 1.0, GRACE 2.0, ACTION and NCDR risk models and in-hospital mortality were assessed and risk model performance was compared. The GRACE 1.0 risk model for prediction of in-hospital mortality discriminated risk superior (c-index 0.84) to its successor GRACE 2.0 (c-index 0.79, p
GRACE1.0vsGRACE2.0 = 0.0008). The NCDR model performed best in discrimination of risk in ACS overall (c-index 0.89; pACTIONvsNCDR < 0.0001; pGRACEvsNCDR < 0.0001) and showed superior performance compared to GRACE in NSTEMI and STEMI subgroups (pGRACEvsNCDR both < 0.02). ACTION and GRACE risk models performed comparable to each other (both c-index 0.84, pGRACEvsACTION = 0.68), with advantages for ACTION in NSTEMI patients (c-index 0.87 vs. 0.84 (GRACE); pGRACEvsACTION = 0.02). ACTION and GRACE 2.0 showed the most accurate calibration of all models., Conclusions: In a contemporary German patient population with ACS, modern NCDR and ACTION risk models showed superior performance in prediction of in-hospital mortality compared to the gold-standard GRACE model., Competing Interests: Declaration of Competing Interest All authors declare: no support from any industry or third-party organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
25. Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease.
- Author
-
Busch L, Stern M, Dannenberg L, Mourikis P, Gröne M, Özaslan G, Heinen Y, Heiss C, Sansone R, Polzin A, and Kelm M
- Subjects
- Aged, Female, Humans, Male, Prospective Studies, Angioplasty adverse effects, Blood Platelets metabolism, Peripheral Arterial Disease blood
- Abstract
Objective : High on-treatment platelet reactivity (HTPR) to dual antiplatelet therapy (DAPT) predicts adverse events in coronary artery disease patients. In peripheral artery disease (PAD) patients, data concerning the clinical impact of HTPR are limited. Therefore, we evaluated the incidence of (i) HTPR to DAPT and (ii) its impact on 6 months outcome after angioplasty. Methods and results : In this prospective single center analysis, we investigated 102 consecutive patients with PAD from 2016 to 2017. All patients underwent peripheral endovascular treatment due to intermittent claudication (Fontaine IIb). Clopidogrel effects were measured using vasodilator-stimulated protein phosphorylation (VASP) assay, aspirin effects by light-transmission aggregometry (LTA). Major adverse limb events (MALE), major adverse cardiac and cerebrovascular events (MACCE) and BARC bleeding (bleeding academic research consortium classification) within 6 months were assessed. HTPR to clopidogrel (n = 37, 36%), to aspirin (n = 11, 11%) and to both (n = 11, 11%) were frequent. Compared to sufficient platelet inhibition by aspirin and clopidogrel (n = 43, 42%), patients with dual HTPR showed a higher risk of MALE at 6 months (27% vs. 7%; hazard ratio [HR]: 4.45; 95% confidence interval [CI]: 1.1 to 67.8; p = .03). This was independent of diabetes, creatinine, body mass index, and age as well as of procedural details in a multivariate logistic regression analysis. MACCE (n = 2) and BARC bleeding rates (n = 2) were low. Conclusion : In this small exploratory study, HTPR was frequent in PAD patients. Furthermore, the results are suggestive that MALE might be associated with dual HTPR. This leads to the hypothesis that optimized antithrombotic regimens post percutaneous transluminal angioplasty should be tested in clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
26. Lipid lowering therapy in cardiovascular disease: From myth to molecular reality.
- Author
-
Mourikis P, Zako S, Dannenberg L, Nia AM, Heinen Y, Busch L, Richter H, Hohlfeld T, Zeus T, Kelm M, and Polzin A
- Subjects
- Animals, Atherosclerosis prevention & control, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Humans, Risk Reduction Behavior, Cardiovascular Diseases prevention & control, Hypolipidemic Agents pharmacology, Lipids blood
- Abstract
Lipid-lowering therapy is one major cornerstone of medical treatment of cardiovascular disease in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are already recommended in current guidelines and were shown to improve lipid profiles and have positive effects on the rate of ischemic events and cardiovascular mortality. Recent studies suggest that the concept of "The lower the better" might be valid at least regarding low density lipoproteins. In addition, lowering lipoprotein (a) still displays a major challenge in lipid therapy. Furthermore, also lowering triglycerides seems to improve cardiovascular outcome. Regarding triglycerides, icosapent ethyl, a polyunsaturated fatty acid recently attracted attention showing cardiovascular risk reduction due to triglyceride lowering. Therefore, new therapeutic strategies and drug classes are eagerly awaited. Targeting LDL, bempedoic acid and the siRNA inclisiran provide promising results. Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. At least, using antisense-oligonucleotides against ApoC-III and Lp(a) resulted in promising outcomes. In this review, current and future options for lipid management are presented depending on different drug classes., Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interest., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
27. Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk.
- Author
-
Brockmeyer M, Wolff G, Krieger T, Lin Y, Karathanos A, Afzal S, Zeus T, Westenfeld R, Polzin A, Heinen Y, Perings S, Kelm M, and Schulze V
- Subjects
- Aged, Female, Germany epidemiology, Humans, Kidney Function Tests methods, Male, Risk Factors, Atrial Appendage surgery, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Hemorrhage etiology, Hemorrhage prevention & control, Postoperative Complications diagnosis, Postoperative Complications epidemiology, Prosthesis Implantation adverse effects, Prosthesis Implantation instrumentation, Prosthesis Implantation methods, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic epidemiology, Risk Adjustment methods, Septal Occluder Device, Stroke etiology, Stroke prevention & control
- Abstract
Background: Patients with chronic kidney disease (CKD) and atrial fibrillation have increased risks for stroke and bleeding under oral anticoagulation (OAC). We investigated an alternative therapy of percutaneous left atrial appendage occlusion (LAAO) in CKD patients in this study. Methods: Consecutive patients undergoing LAAO were included in a retrospective analysis and stratified for kidney function into CKD/Non-CKD groups (cutoff eGFR 60 ml/min). Procedural characteristics, in-hospital and follow-up events were analysed and compared between groups. Results: LAAO was performed in 146 patients (81 CKD; 65 Non-CKD), mean follow-up was 391 days. Groups differed in eGFR (40.1 (CKD) vs. 75.1 (Non-CKD) ml/min) and CHA
2 DS2 VASc scores (4.65 ± 1.3 (CKD) vs. 4.06 ± 1.4 (Non-CKD)). Procedural success was 98.6%, contrast-induced acute kidney injury was significantly more frequent in CKD patients (11.1% vs. 0%; p = .004). Follow-up mortality was higher in CKD (10.5/100 PY vs. 4.2/100 PY; p = .156). Follow-up stroke rates were 2.3/100 (CKD) patient-years (PY) and 1.4/100 PY (Non-CKD) ( p = 1.000), corresponding to a relative risk reduction (RRR) of 60% (all), 68% (CKD) and 71% (Non-CKD) compared to expected stroke rates. Follow-up major bleeding rates were 3.5/100 PY (CKD) and 4.2/100 PY (Non-CKD), corresponding to RRR of 57% (all), 61% (CKD) and 53% (Non-CKD) compared to OAC. Conclusions: Left atrial appendage occlusion shows comparable efficacy for stroke and bleeding prevention in CKD and Non-CKD patients. CKD patients experience more adverse events during follow-up and a significantly increased risk for periprocedural contrast-induced acute kidney injury.- Published
- 2020
- Full Text
- View/download PDF
28. Validation of National Cardiovascular Data Registry risk models for mortality, bleeding and acute kidney injury in interventional cardiology at a German Heart Center.
- Author
-
Wolff G, Lin Y, Quade J, Bader S, Kosejian L, Brockmeyer M, Karathanos A, Parco C, Krieger T, Heinen Y, Perings S, Albert A, Icks A, Kelm M, and Schulze V
- Subjects
- Acute Kidney Injury diagnosis, Acute Kidney Injury mortality, Aged, Contrast Media administration & dosage, Coronary Angiography mortality, Female, Germany epidemiology, Hemorrhage diagnosis, Hemorrhage mortality, Hospital Mortality, Humans, Male, Middle Aged, Non-ST Elevated Myocardial Infarction diagnostic imaging, Non-ST Elevated Myocardial Infarction mortality, Percutaneous Coronary Intervention mortality, Predictive Value of Tests, Radiography, Interventional mortality, Reproducibility of Results, Retrospective Studies, Risk Assessment, Risk Factors, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction mortality, Time Factors, Treatment Outcome, Acute Kidney Injury chemically induced, Contrast Media adverse effects, Coronary Angiography adverse effects, Decision Support Techniques, Hemorrhage epidemiology, Non-ST Elevated Myocardial Infarction therapy, Percutaneous Coronary Intervention adverse effects, Radiography, Interventional adverse effects, ST Elevation Myocardial Infarction therapy
- Abstract
Background and Purpose: The National Cardiovascular Data Registry (NCDR) risk scores for mortality, bleeding and acute kidney injury (AKI) are accurate outcome predictors of coronary catheterization procedures in North American populations. However, their application in German clinical practice remained elusive and we thus aimed to verify their use., Methods: NCDR scores for mortality, bleeding and AKI and corresponding clinical outcomes were retrospectively assessed in patients undergoing catheterization for ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or for elective coronary procedures at a German Heart Center from 2014 to 2017. Risk model performance was assessed using receiver-operating-characteristic curves (discrimination) and graphical analysis/logistic regression (calibration)., Results: A total of 1637 patients were included, procedures were performed for STEMI (565 patients, 34.5%), NSTEMI (572 patients, 34.9%) and elective purposes (500 patients, 30.5%); 6% (13% of STEMI and 5% of NSTEMI patients) presented in cardiogenic shock and 3% with resuscitated cardiac arrest. Radial access was used in 38% of procedures and cross-over was necessary in 5%; PCI was performed in 60% of procedures. In-hospital mortality was 6.3% (STEMI 14.5%; NSTEMI 3.7%; elective 0%) and major bleedings occurred in 5.6% (STEMI 10.6%; NSTEMI 5.4%; elective 0.2%); AKI was detected in 18.1% of patients (STEMI 23.7%; NSTEMI 27.3%; elective 1.4%), amounting to KDIGO stage I/II/III in 11.5%/3.5%/3.2%. NCDR risk models discriminated very well for mortality [AUC 0.93 with 95% confidence interval (CI) 0.91-0.95] and well for major bleeding (AUC 0.82, CI 0.78-0.86) and any AKI (AUC 0.83, CI 0.81-0.86). Discrimination in the subgroup of patients with PCI was comparable (mortality: AUC 0.90; major bleeding: AUC 0.78; any AKI: AUC 0.79). However, calibration showed considerable underestimation of mortality and AKI in high-risk patients, while major bleeding was consistently overestimated (Hosmer-Lemeshow p < 0.02 for all outcomes)., Conclusions: The NCDR risk models showed excellent performance in discriminating high-risk from low-risk patients in contemporary German interventional cardiology. Model calibration for adverse event probability prediction, however, is limited and demands recalibration, especially in high-risk patients.
- Published
- 2020
- Full Text
- View/download PDF
29. [Update ESC-Guideline: Management of cardiovascular diseases during pregnancy - What is important?]
- Author
-
Klein K, Karathanos A, and Heinen Y
- Subjects
- Female, Humans, Practice Guidelines as Topic, Pregnancy, Cardiovascular Diseases therapy, Pregnancy Complications, Cardiovascular therapy
- Abstract
The treatment of pregnant patients with a cardiovascular disease is a special challenge to deal with. Before getting pregnant all cardiac patients should get medical advice accordingly to their risk profile in the modified World Health Organization classification of maternal cardiovascular risk. This article has the aim to give an overview of the new or changed recommendations of the new ESC-Guideline for the management of cardiovascular diseases during pregnancy., Competing Interests: Die Autoren geben an, dass kein Interessenkonflikt besteht., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2019
- Full Text
- View/download PDF
30. Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis.
- Author
-
Karathanos A, Lin Y, Dannenberg L, Parco C, Schulze V, Brockmeyer M, Jung C, Heinen Y, Perings S, Zeymer U, Kelm M, Polzin A, and Wolff G
- Subjects
- Drug Therapy, Combination, Global Health, Humans, Platelet Aggregation Inhibitors therapeutic use, Randomized Controlled Trials as Topic, ST Elevation Myocardial Infarction blood, ST Elevation Myocardial Infarction mortality, Survival Rate trends, Abciximab therapeutic use, Eptifibatide therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, ST Elevation Myocardial Infarction drug therapy, Tirofiban therapeutic use
- Abstract
Background: Guidelines recommend adjunct glycoprotein IIb/IIIa inhibitors (GPIs) only in selected patients with acute ST-segment elevation myocardial infarction (STEMI). This study aimed to evaluate routine GPI use in STEMI treated with primary percutaneous coronary intervention., Methods: Online databases were searched for randomized controlled trials of routine GPI vs control therapy in STEMI. Data from retrieved studies were abstracted and evaluated in a comprehensive meta-analysis. Twenty-one randomized controlled trials with 8585 patients were included: 10 trials randomized tirofiban, 9 abciximab, 1 trial eptifibatide, and 1 trial used abciximab+tirofiban; only 1 trial used dual antiplatelet therapy with prasugrel/ticagrelor., Results: Routine GPI use was associated with a significant reduction in all-cause mortality at 30 days (2.4% [GPI] vs 3.2%; risk ratio [RR], 0.72; P = 0.01) and 6 months (3.7% vs 4.8%; RR, 0.76; P = 0.02), and a reduction in recurrent myocardial infarction (1.1% vs 2.1%; RR, 0.55; P = 0.0006), repeat revascularization (2.5% vs 4.1%; RR, 0.63; P = 0.0001), thrombolysis in myocardial infarction flow <3 after percutaneous coronary intervention (5.4% vs 8.2%; RR, 0.61; P < 0.0001), and ischemic stroke (RR, 0.42; P = 0.04). Major (4.7% vs 3.4%; RR, 1.35; P = 0.005) and minor bleedings (7.2% vs 5.1%; RR, 1.39; P = 0.006) but not intracranial bleedings (0.1% vs 0%; RR, 2.7; P = 0.37) were significantly increased under routine GPI., Conclusions: Routine GPI administration in STEMI resulted in a reduction in mortality, driven by reductions in recurrent ischemic events-however predominantly in pre-prasugrel/ticagrelor trials. Trials with contemporary STEMI management are needed to confirm these findings., (Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
31. Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis.
- Author
-
Lin Y, Schulze V, Brockmeyer M, Parco C, Karathanos A, Heinen Y, Gliem M, Hartung HP, Antoch G, Jander S, Turowski B, Perings S, Kelm M, and Wolff G
- Subjects
- American Heart Association, Endovascular Procedures, Humans, Practice Guidelines as Topic, Survival Rate, United States, Brain Ischemia surgery, Intracranial Hemorrhages epidemiology, Mortality, Stroke surgery, Thrombectomy methods
- Abstract
Importance: Although endovascular thrombectomy (EVT) in acute ischemic stroke is recommended by guidelines to improve functional recovery, thus far there are insufficient data on its association with mortality., Objective: To identify guideline-relevant trials of EVT vs medical therapy reporting 90-day mortality and perform a meta-analysis., Data Sources: All randomized clinical trials cited for recommendations on EVT vs medical therapy in the latest 2018 American Stroke Association/American Heart Association guidelines., Study Selection: Ten American Stroke Association/American Heart Association guideline-relevant randomized clinical trials of EVT vs medical therapy were selected for inclusion. Two EVT trials were excluded owing to infrequent use of EVT., Data Extraction and Synthesis: Data were abstracted by 2 independent investigators and double-checked by 4 others. Singular study data were integrated using the Cochran-Mantel-Haenszel method and a random-effects model to compute summary statistics of risk ratios (RR) with 95% CIs., Main Outcomes and Measures: Risk of 90-day mortality and 90-day intracranial hemorrhage was analyzed; sensitivity analyses were performed in early-window EVT trials (which included patients from the onset of symptoms onward) vs late-window EVT trials (which included patients from 6 hours after onset of symptoms onward)., Results: In 10 trials with 2313 patients, EVT significantly reduced the risk for 90-day mortality by 3.7% compared with medical therapy (15.0% vs 18.7%; RR, 0.81; 95% CI, 0.68-0.98; P = .03). Trends were similar in early-window (RR, 0.83; 95% CI, 0.67-1.01; P = .06) and late-window trials only (RR, 0.76; 95% CI, 0.41-1.40; P = .38). There was no difference in the risk for intracranial hemorrhage in EVT vs medical therapy (4.2% vs 4.0%; RR, 1.11; 95% CI, 0.71-1.72; P = .65). Limitations of the studies include trial protocol heterogeneity and bias originating from prematurely terminated trials., Conclusions and Relevance: This meta-analysis of all evidence on EVT cited in the 2018 American Stroke Association/American Heart Association guidelines shows significant benefits for survival during the first 90 days after acute ischemic stroke compared with medical therapy alone.
- Published
- 2019
- Full Text
- View/download PDF
32. [Emergency sonography of the heart - step by step].
- Author
-
Klein K, Karathanos A, Heinen Y, and Zeus T
- Subjects
- Aortic Valve Stenosis diagnostic imaging, Cardiac Tamponade diagnostic imaging, Emergency Treatment instrumentation, Heart Atria diagnostic imaging, Heart Failure diagnostic imaging, Heart Ventricles diagnostic imaging, Humans, Mitral Valve Insufficiency diagnostic imaging, Pericardial Effusion diagnostic imaging, Vena Cava, Inferior diagnostic imaging, Ventricular Function, Left, Ventricular Function, Right, Aorta diagnostic imaging, Cardiovascular Diseases diagnostic imaging, Echocardiography methods, Emergency Treatment methods, Heart diagnostic imaging
- Abstract
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2018
- Full Text
- View/download PDF
33. Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies.
- Author
-
Sansone R, Ottaviani JI, Rodriguez-Mateos A, Heinen Y, Noske D, Spencer JP, Crozier A, Merx MW, Kelm M, Schroeter H, and Heiss C
- Subjects
- Adult, Biomarkers blood, Blood Pressure drug effects, C-Reactive Protein metabolism, Caffeine administration & dosage, Catechin blood, Catechin urine, Cross-Over Studies, Double-Blind Method, Endpoint Determination, Humans, Male, Pulse Wave Analysis, Theobromine administration & dosage, Vascular Stiffness drug effects, Vasodilation drug effects, Young Adult, Cacao chemistry, Cardiovascular System drug effects, Flavonols administration & dosage, Polyphenols administration & dosage, Xanthines administration & dosage
- Abstract
Background: Cocoa flavanol intake, especially that of (-)-epicatechin, has been linked to beneficial effects on human cardiovascular function. However, cocoa also contains the methylxanthines theobromine and caffeine, which may also affect vascular function., Objective: We sought to determine whether an interaction between cocoa flavanols and methylxanthines exists that influences cocoa flavanol-dependent vascular effects., Design: Test drinks that contained various amounts of cocoa flavanols (0-820 mg) and methylxanthines (0-220 mg), either together or individually, were consumed by healthy volunteers (n = 47) in 4 different clinical studies-3 with a randomized, double-masked crossover design and 1 with 4 parallel crossover studies. Vascular status was assessed by measuring flow-mediated vasodilation (FMD), brachial pulse wave velocity (bPWV), circulating angiogenic cells (CACs), and blood pressure before and 2 h after the ingestion of test drinks., Results: Although cocoa flavanol intake increased FMD 2 h after intake, the consumption of cocoa flavanols with methylxanthines resulted in a greater enhancement of FMD. Methylxanthine intake alone did not result in statistically significant changes in FMD. Cocoa flavanol ingestion alone decreased bPWV and diastolic blood pressure and increased CACs. Each of these changes was more pronounced when cocoa flavanols and methylxanthines were ingested together. It is important to note that the area under the curve of the plasma concentration of (-)-epicatechin metabolites over time was higher after the co-ingestion of cocoa flavanols and methylxanthines than after the intake of cocoa flavanols alone. Similar results were obtained when pure (-)-epicatechin and the methylxanthines theobromine and caffeine were consumed together., Conclusion: A substantial interaction between cocoa flavanols and methylxanthines exists at the level of absorption, in which the methylxanthines mediate an increased plasma concentration of (-)-epicatechin metabolites that coincides with enhanced vascular effects commonly ascribed to cocoa flavanol intake. This trial was registered at clinicaltrials.gov as NCT02149238., (© 2017 American Society for Nutrition.)
- Published
- 2017
- Full Text
- View/download PDF
34. Microglial Priming and Alzheimer's Disease: A Possible Role for (Early) Immune Challenges and Epigenetics?
- Author
-
Hoeijmakers L, Heinen Y, van Dam AM, Lucassen PJ, and Korosi A
- Abstract
Neuroinflammation is thought to contribute to Alzheimer's disease (AD) pathogenesis that is, to a large extent, mediated by microglia. Given the tight interaction between the immune system and the brain, peripheral immune challenges can profoundly affect brain function. Indeed, both preclinical and clinical studies have indicated that an aberrant inflammatory response can elicit behavioral impairments and cognitive deficits, especially when the brain is in a vulnerable state, e.g., during early development, as a result of aging, or under disease conditions like AD. However, how exactly peripheral immune challenges affect brain function and whether this is mediated by aberrant microglial functioning remains largely elusive. In this review, we hypothesize that: (1) systemic immune challenges occurring during vulnerable periods of life can increase the propensity to induce later cognitive dysfunction and accelerate AD pathology; and (2) that "priming" of microglial cells is instrumental in mediating this vulnerability. We highlight how microglia can be primed by both neonatal infections as well as by aging, two periods of life during which microglial activity is known to be specifically upregulated. Lasting changes in (the ratios of) specific microglial phenotypes can result in an exaggerated pro-inflammatory cytokine response to subsequent inflammatory challenges. While the resulting changes in brain function are initially transient, a continued and/or excess release of such pro-inflammatory cytokines can activate various downstream cellular cascades known to be relevant for AD. Finally, we discuss microglial priming and the aberrant microglial response as potential target for treatment strategies for AD.
- Published
- 2016
- Full Text
- View/download PDF
35. Local association between endothelial dysfunction and intimal hyperplasia: relevance in peripheral artery disease.
- Author
-
Heinen Y, Stegemann E, Sansone R, Benedens K, Wagstaff R, Balzer J, Rassaf T, Lauer T, Kelm M, and Heiss C
- Subjects
- Adult, Aged, Atherosclerosis pathology, Brachial Artery diagnostic imaging, Carotid Intima-Media Thickness, Case-Control Studies, Endothelium, Vascular diagnostic imaging, Female, Femoral Artery diagnostic imaging, Humans, Lower Extremity blood supply, Male, Middle Aged, Peripheral Arterial Disease pathology, Plaque, Atherosclerotic diagnostic imaging, Plaque, Atherosclerotic pathology, Regional Blood Flow, Risk Factors, Vascular Stiffness, Vasodilation, Atherosclerosis diagnostic imaging, Brachial Artery pathology, Endothelium, Vascular pathology, Endothelium, Vascular physiopathology, Femoral Artery pathology, Peripheral Arterial Disease diagnostic imaging
- Abstract
Background: Endothelial dysfunction is a key factor in the development of atherosclerosis. Commonly, endothelial function is determined in the brachial artery, whereas patients with peripheral artery disease (PAD) present with lower limb atherosclerosis. We hypothesized that in PAD, a segmental or local association exists between endothelial dysfunction and atherosclerotic structural changes., Methods and Results: We used ultrasound to study endothelial function as flow-mediated vasodilation, intima media thickness, and local stiffness of the superficial femoral artery (SFA) and brachial artery (BA). PAD patients with symptomatic SFA or below-the-knee disease were compared with age-matched patients without PAD and young healthy controls. PAD patients with SFA or below-the-knee disease exhibited endothelial dysfunction of the proximal SFA (flow-mediated vasodilation: 3.9±0.6%, 3.7±0.6%) compared with healthy controls (7.4±1.0%) and patients without PAD (5.4±0.6%). Brachial artery flow-mediated vasodilation values were not different in PAD patients with SFA or below-the-knee disease compared with patients without PAD, but they were significantly lower than those of healthy controls. Endothelial dysfunction correlated with increased intima media thickness or plaque thickness at the site of flow-mediated vasodilation measurement across vascular sites. In PAD patients with SFA disease, SFA flow-mediated vasodilation was further impaired within and distal to stenosis (prestenosis 3.9±0.6%, intrastenosis 2.3±0.7%, poststenosis 2.5±0.6%) and recovered within 24 hours after SFA balloon angioplasty to prestenotic values but not to the brachial artery or SFA values in patients without PAD or controls., Conclusion: A close association exists between local endothelial function and atherosclerotic structural remodeling, suggesting that in PAD, local and segmental factors-in addition to systemic factors-influence local endothelial function. Our data point toward a pathophysiological role for lower extremity endothelial dysfunction in PAD., (© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2015
- Full Text
- View/download PDF
36. Dietary inorganic nitrate mobilizes circulating angiogenic cells.
- Author
-
Heiss C, Meyer C, Totzeck M, Hendgen-Cotta UB, Heinen Y, Luedike P, Keymel S, Ayoub N, Lundberg JO, Weitzberg E, Kelm M, and Rassaf T
- Subjects
- Animals, Cross-Over Studies, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Mice, Nitrates administration & dosage, Nitrates blood, Diet, Neovascularization, Physiologic, Nitrates pharmacology
- Abstract
Nitric oxide (NO) was implicated in the regulation of mobilization and function of circulating angiogenic cells (CACs). The supposedly inert anion nitrate, abundant in vegetables, can be stepwise reduced in vivo to form nitrite, and consecutively NO, representing an alternative to endogenous NO formation by NO synthases. This study investigated whether inorganic dietary nitrate influences mobilization of CACs. In a randomized double-blind fashion, healthy volunteers ingested 150 ml water with 0.15 mmol/kg (12.7 mg/kg) of sodium nitrate, an amount corresponding to 100-300 g of a nitrate-rich vegetable, or water alone as control. Mobilization of CACs was determined by the number of CD34(+)/KDR(+) and CD133(+)/KDR(+) cells using flow cytometry and the mobilization markers stem cell factor (SCF) and stromal cell-derived factor-1a (SDF-1α) were determined in plasma via ELISA. Nitrite and nitrate were measured using high-performance liquid chromatography and reductive gas-phase chemiluminescence, respectively. NOS-dependent vasodilation was measured as flow-mediated vasodilation. Further mechanistic studies were performed in mice after intravenous application of nitrite together with an NO scavenger to identify the role of nitrite and NO in CAC mobilization. Nitrate ingestion led to a rise in plasma nitrite together with an acute increase in CD34(+)/KDR(+) and CD133(+)/KDR(+)-CACs along with increased NOS-dependent vasodilation. This was paralleled by an increase in SCF and SDF-1α and the maximal increase in plasma nitrite correlated with CD133(+)/KDR(+)-CACs (r=0.73, P=0.016). In mice, nitrate given per gavage and direct intravenous injection of nitrite led to CAC mobilization, which was abolished by the NO scavenger cPTIO, suggesting that nitrite mediated its effect via formation of NO. Dietary inorganic nitrate acutely mobilizes CACs via serial reduction to nitrite and NO. The nitrate-nitrite-NO pathway could offer a novel nutritional approach for regulation of vascular regenerative processes., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
37. Characterization of macro-and microvascular function and structure in patients with type 2 diabetes mellitus.
- Author
-
Keymel S, Heinen Y, Balzer J, Rassaf T, Kelm M, Lauer T, and Heiss C
- Abstract
Objective: Diabetes mellitus (DM) leads to accelerated progression of arteriosclerosis with an increased risk of coronary events in comparison to non-diabetic patients with coronary artery disease (CAD). The precise and early detection of DM-induced vascular alterations is crucial to identify patients with high risk for cardiovascular complications. Thus, we aimed at simultaneously characterizing functional, physicomechanical, and structural vascular alterations in diabetic patients using a non-invasive approach., Research Design and Methods: In CAD patients with and without type 2 diabetes mellitus (n=50), we non-invasively measured flow-mediated dilation (FMD) of the brachial artery as a marker for endothelial function, fractional diameter changes (FDC) as a marker for physicomechanical properties, intima-media thickness (IMT) as a marker for structural properties, and forearm blood flow (FBF) as a marker for microvascular function., Results: DM was associated with reduced FMD (2.5±0.2 vs 4.8±0.4%; p≤0.001) indicating impaired macrovascular endothelial function. In parallel, reduced FDC (0.024±0.002 vs 0.034±0.004; p≤0.05) and increased IMT (0.38±0.01 vs 0.31±0.01mm; p≤0.001) indicated increased stiffness and enhanced structural alterations. Furthermore, reduced forearm blood flow during reactive hyperemia (10.7±1.0 vs. 15.3±1.4mL/min*100mL; p≤0.05) was found indicating microvascular dysfunction. Plasma glucose and HbA(1c) correlated with FMD (glucose: r=-0.32; HbA(1c): r=-0.45), IMT (glucose: r=0.54; HbA(1c): r=0.48) and FBF (glucose: r=-0.30) suggesting diabetes-specific effects on vascular properties., Conclusion: In patients with CAD, DM leads to functional and structural vascular alterations of the peripheral vasculature which are determined by the control of the disease underlining the relevance of a strict control of the DM to prevent accelerated atherosclerosis.
- Published
- 2011
38. Nitric oxide synthase expression and functional response to nitric oxide are both important modulators of circulating angiogenic cell response to angiogenic stimuli.
- Author
-
Heiss C, Schanz A, Amabile N, Jahn S, Chen Q, Wong ML, Rassaf T, Heinen Y, Cortese-Krott M, Grossman W, Yeghiazarians Y, and Springer ML
- Subjects
- Cell Movement, Humans, Neovascularization, Physiologic, Chemotaxis physiology, Endothelial Cells physiology, Nitric Oxide physiology, Nitric Oxide Synthase biosynthesis, Stem Cells physiology, Vascular Endothelial Growth Factor A metabolism
- Abstract
Objective: Circulating angiogenic cells (CACs), also termed endothelial progenitor cells, play an integral role in vascular repair and are functionally impaired in coronary artery disease (CAD). The role of nitric oxide (NO) in CAC function is poorly understood. We hypothesized that CAC migration toward angiogenic signals is modulated by both NO synthase (NOS) expression and functional response to NO., Methods and Results: Similar to endothelial cells, CAC chemotaxis to vascular endothelial growth factor (VEGF) was blocked by inhibition of NOS, phosphatidylinositol 3-kinase, or guanylyl cyclase or by treatment with an NO scavenger. Addition of an NO donor (S-nitroso-N-acetylpenicillamine) and the NOS substrate l-arginine increased random cell migration (chemokinesis) and enhanced VEGF-dependent chemotaxis. Healthy CACs expressed endothelial NOS, but endothelial NOS was not detected in CAD patient CACs. Both chemokinesis and chemotaxis to VEGF of patient CACs were decreased compared with healthy CACs but were restored to healthy values by S-nitroso-N-acetylpenicillamine. In parallel, CAD patients exhibited lower flow-mediated vasodilation and plasma NO source nitrite than young, healthy subjects, indicating endothelial dysfunction with reduced NO bioavailability., Conclusions: NOS activity is required for CAC chemotaxis. In CAD patients, impairment of NOS expression and NO bioavailability, rather than response to NO, may contribute to dysfunction of CACs and limit their regenerative capacity.
- Published
- 2010
- Full Text
- View/download PDF
39. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice.
- Author
-
Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, and Schulz R
- Subjects
- Age Factors, Animals, Mice, Mice, Inbred C57BL, Mice, Knockout, Myocardial Infarction therapy, Myocardial Ischemia, Myocardial Reperfusion, Phosphorylation, STAT3 Transcription Factor metabolism, STAT3 Transcription Factor physiology, Ischemic Preconditioning, Myocardial, STAT3 Transcription Factor deficiency
- Abstract
The cardioprotection by ischemic preconditioning is lost in aged wild-type and in STAT3 (signal transducer and activator of transcription 3)-deficient mice. The aim of the present study was to analyze whether or not ischemic postconditioning (iPoco) was effective in aged mice hearts and whether iPoco was dependent on STAT3. Young (3 months) and aged (>13 months) C57Bl6/J mice underwent 30 minutes of ischemia and 2 hours of reperfusion without or with iPoco (3 cycles of 10 seconds of ischemia/10 seconds of reperfusion [3x10] or 5 cycles of 5 seconds of ischemia/5 seconds of reperfusion [5x5] at the beginning of reperfusion). In young mice, both iPoco3x10 and iPoco5x5 reduced infarct size (IS), whereas in aged mice, only iPoco5x5 was effective in reducing IS. In young mice, iPoco3x10 increased the phosphorylated over total STAT3 (phosphorylated STAT3/STAT3) ratio at 10 minutes of reperfusion in the postconditioned anterior wall compared with the control posterior wall. In aged mice hearts, total STAT3 and phosphorylated STAT3/STAT3 in the anterior wall at reperfusion were reduced compared with young mice hearts. In young mice hearts subjected to iPoco3x10 but pretreated with the JAK-2 inhibitor AG-490, phosphorylated STAT3/STAT3 was reduced in the anterior wall compared with untreated young mice hearts, and IS reduction by iPoco3x10 was abolished. Furthermore, in young mice with a cardiomyocyte-restricted deletion of STAT3, iPoco3x10 failed to reduce IS, whereas iPoco5x5 reduced IS. Thus, cardioprotection by iPoco is dependent on the postconditioning protocol in aged and STAT3-deficient hearts. The reduced levels of STAT3 with increasing age may contribute to the age-related loss of iPoco.
- Published
- 2008
- Full Text
- View/download PDF
40. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43.
- Author
-
Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, and Schulz R
- Subjects
- Animals, Blotting, Western, Female, Heart Ventricles metabolism, Heart Ventricles pathology, Mice, Mice, Inbred C57BL, Myocardial Infarction pathology, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Aging metabolism, Connexin 43 metabolism, Gap Junctions metabolism, Ischemic Preconditioning, Myocardial, Mitochondria metabolism, Myocardial Infarction metabolism
- Abstract
Connexin 43 (Cx43) is localized at left ventricular (LV) gap junctions and in cardiomyocyte mitochondria. A genetically induced reduction of Cx43 as well as blockade of mitochondrial Cx43 import abolishes the infarct size (IS) reduction by ischemic preconditioning (IP). With progressing age, Cx43 content in ventricular and atrial tissue homogenates is reduced. We now investigated whether or not 1) the mitochondrial Cx43 content is reduced in aged mice hearts and 2) IS reduction by IP is lost in aged mice hearts in vivo. Confirming previous results, sarcolemmal Cx43 content was reduced in aged (>13 mo) compared with young (<3 mo) C57Bl/6 mice hearts, whereas the expression levels of protein kinase C epsilon and endothelial nitric oxide synthase remained unchanged. Also in mitochondria isolated from aged mice LV myocardium, Western blot analysis indicated a 40% decrease in Cx43 content compared with mitochondria isolated from young mice hearts. In young mice hearts, IP by one cycle of 10 min ischemia and 10 min reperfusion reduced IS (% of area at risk) following 30 min regional ischemia and 120 min reperfusion from 67.7 +/- 3.3 (n = 17) to 34.2 +/- 6.6 (n = 5, P < 0.05). In contrast, IP's cardioprotection was lost in aged mice hearts, since IS in nonpreconditioned (57.5 +/- 4.0, n = 10) and preconditioned hearts (65.4 +/- 6.3, n = 8, P = not significant) was not different. In conclusion, mitochondrial Cx43 content is decreased in aged mouse hearts. The reduced levels of Cx43 may contribute to the age-related loss of cardioprotection by IP.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.